Academic literature on the topic 'Pharmaceutical Marketing Services Inc'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical Marketing Services Inc.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Pharmaceutical Marketing Services Inc"
1
Dulay, G., E. Choy, T. Barnes, D. Chagadama, Z. Cole, A. Malaviya, S. Robinson, et al. "SAT0609-HPR DELPHI CONSENSUS FOR THE OPTIMAL TREATMENT & MANAGEMENT OF COMPLEX RHEUMATOID ARTHRITIS (RA) PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1264.1–1265. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3256.
Full textAbstract:
Background:A significant proportion of patients with rheumatoid arthritis (RA) have additional considerations that must be taken into account for managing their disease.1These include; co-morbidities, extra-articular manifestations and poor prognostic factors.2-5Tailored management could reduce the burden on patients, the health system and wider society.The ‘complex’ RA patient group is ill-defined and no specific recommendations exist for their optimal management and treatment.Objectives:A group of UK Rheumatology experts aimed to provide a set of recommendations to support consistent and high quality management, grounded in current evidence, expert opinion and best practice.Methods:A steering group meeting identified priority topics associated with complex RA.Table 1.Topics for consensusTopicNo. of statementsDefinition of ‘complex’ RA from a medical perspective19Definition of patient factors that may contribute to ‘complex’ RA3Outcomes for RA patients with co-morbidities and/or extra articular manifestations5Prescribing options for ‘complex’ RA8Evidence vs. best practice requirements4Burden of ‘complex’ RA4TOTAL NUMBER OF STATEMENTS43For each topic, the group defined statements they all agreed with. Delphi methodology was used to ratify these statements with rheumatology peers.High levels of agreement (over 70%) were achieved in the first round, the group proceeded to formulate the recommendations.Figure 1.Responses received (n=163)Figure 2.Consensus Plot (total responses n=163)Conclusion:These recommendations are offered:Healthcare professionals (HCPs) should consider a patient’s complexity (including clinical co-morbidities, extra-articular manifestations and poor prognostic factors) prior to making treatment decisions;HCPs should take into account a patient’s psychosocial factors and health literacy prior to making treatment decisions;Patient specific outcomes for complex RA should always be proactively agreed with the individual and/or their carers;The local healthcare system should consider the overall costs of complex RA, beyond drug acquisition costs to allow flexibility of prescribing choices, as necessary in this group of patients;Local treatment pathways should reflect that treatments with particular modes of action are more suitable for individual patients with complex RA.Management of complex RA patients should extend beyond guidelines and recognise additional sources of evidence including; clinical studies, Real World Experience (RWE) and post-marketing surveillance.References:[1]Uhlig T, Moe RH, Kvien TK. The burden of disease in rheumatoid arthritis. Pharmacoeconomics 2014;32:841–51[2]Dougados M, et al. Ann Rheum Dis 2014;73:62–68.[3]Parodi M et al,Rheumatism, 2005, 57(3): 154-60.[4]Young A & Koduri G. Best Pract Res Clin Rheumatol. 2007 Oct;21(5):907-27.[5]Holroyd CR, et al. Rheumatology 2019;58:e3-e42Acknowledgments:Support for medical writing/editorial assistance, provided by Tim Warren at Triducive was funded by Roche Products Ltd. & Chugai Pharma Ltd. in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).Disclosure of Interests:Gurdeep Dulay Grant/research support from: Educational grants to attend congress meetings/conferences from Roche, Chugai, UCB, Internis, Pfizer, Lilly, Sandoz, Consultant of: Honoraria for advisory board services from Roche, Chugai, Novartis, Speakers bureau: Speaker fees from Roche, Chugai, Novartis, Amgen, Lilly, Sandoz, Ernest Choy Grant/research support from: Amgen, Bio-Cancer, Chugai Pharma, Ferring Pharmaceuticals, Novimmune, Pfizer, Roche, UCB, Consultant of: AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceuticals, GlaxoSmithKline, Hospita, Ionis, Janssen, Jazz Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Merrimack Pharmaceutical, Napp, Novartis, Novimmune, ObsEva, Pfizer, R-Pharm, Regeneron Pharmaceuticals, Inc., Roche, SynAct Pharma, Sanofi Genzyme, Tonix, UCB, Speakers bureau: Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharma, Eli Lilly, Hospira, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Sanofi-Aventis, UCB, Theresa Barnes Consultant of: Ad boards for Roche, Actelion and Abbvie, Speakers bureau: Speaker for MSD, UCB, Pfizer, Abbvie, Actelion, Roche and BMS, Debbie Chagadama Consultant of: Roche, Chugai, BI, Speakers bureau: Roche, Chugai, BI, Zoe Cole Consultant of: Consultancy work for Roche, Lilly, Gilead, Abbvie, Pfizer, UCB, Speakers bureau: Lilly, BMS, Abbvie, Pfizer, UCB, Janssen, Anshuman Malaviya Consultant of: Roche, Chugai, MSD, Pfizer, Novartis, Lily, BMS, Speakers bureau: Roche, BMS, Pfizer, MSD, Sandra Robinson Consultant of: Eli Lilly for Education Nurse Meeting, David Walker Grant/research support from: Gilead, Consultant of: Gilead, Lilly, Pfizer, Roche, Speakers bureau: Lilly, Pfizer, Roche, Chris Daly Employee of: Roche, Nicola Savill Employee of: Roche, Tim Warren Consultant of: Roche, Employee of: AstraZeneca, Nick Williams Shareholder of: MSD, Consultant of: Roche, Employee of: MSD
2
McDonough, Randy P., Elizabeth S. Pithan, William R. Doucette, and Michael J. Brownlee. "Marketing Pharmaceutical Care Services." Journal of the American Pharmaceutical Association (1996) 38, no. 6 (November 1998): 667–95. http://dx.doi.org/10.1016/s1086-5802(16)30401-6.
Full text
3
Bien, Timothy. "Developing Innovative Pharmaceutical Services." Journal of Pharmaceutical Marketing & Management 8, no. 4 (September 26, 1994): 77–86. http://dx.doi.org/10.1300/j058v08n04_08.
Full text
4
Joyce, George. "Consumer Patronage for Pharmaceutical Services." Journal of Pharmaceutical Marketing & Management 3, no. 1 (October 27, 1988): 3–17. http://dx.doi.org/10.1300/j058v03n01_02.
Full text
5
Shepherd, Marvin D. "Defining and Marketing Value Added Services." American Pharmacy 35, no. 1 (January 1995): 46–55. http://dx.doi.org/10.1016/s0160-3450(16)33865-x.
Full text
6
Smith, Harry. "Patron Experience and Satisfaction with Pharmaceutical Services." Journal of Pharmaceutical Marketing & Management 7, no. 3 (June 7, 1993): 81–93. http://dx.doi.org/10.1300/j058v07n03_06.
Full text
7
Holdford, David. "The Relative Importance Consumers Place on Pharmaceutical Services." Journal of Pharmaceutical Marketing & Management 11, no. 4 (May 8, 1997): 55–68. http://dx.doi.org/10.1300/j058v11n04_05.
Full text
8
Tootelian, Dennis. "Computer Applications for Marketing Services, Monitoring Patients." American Pharmacy 32, no. 11 (November 1992): 57–65. http://dx.doi.org/10.1016/s0160-3450(15)30947-8.
Full text
9
Smolynets, I. B., B. V. Gutyj, І. І. Khariv, O. Y. Petryshak, and R. I. Lytvyn. "PHARMACEUTICAL MARKETING: OBJECTIVES AND TYPES." Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies 18, no. 2 (August 5, 2016): 151–54. http://dx.doi.org/10.15421/nvlvet6929.
Full textAbstract:
Pharmaceutical marketing objectives and types depending on demand state are overviewed in this article. Pharmaceutical enterprise has always a certain idea of the desired level of market demand. In practice demand is not always in accordance with level that has been predicted. One can strictly outline eight situations that characterise the state of demand. Every such situation is in accordance with certain marketing managerial task and its types. Conversional marketing is related tomedicines’ negative demand and medical services availability, e.g. such kind of situation, when they cannot find their own buyer at substantial part of potential market. Stimulating marketing is related to demand absence, e.g. state, when potential market does not reveal (or almost does not reveal) interest towards concrete proposal. Marketing that develops is related to medicines demand, that is at the stage of formation (hidden demand). Potential (hidden) demand occurs when certain consumers part need real problem solving, that cannot remain satisfied with the medicines and medical services that are available at the market. Remarketing is related to medicines or medical services decreasing demand situation for a particular period of time, as a result of moral degradation, not consideration sale stimulation tools, advertising updates, and competition factors. Sync marketing (irregular marketing) is related to uneven demand, its fluctuation: seasonality (medicines against a cold,stomach–intestinal diseases and etc.); daily (pharmacies are more often attended during the weekdays, less – at the weekend); hourly (pharmacies are most often attended in a period of time from eight to eleven in the morning and from five to seven in the evening accordingly to research data). Supportive marketing is related to satisfied demand availability. Demarketing is related to surplus of demand, so medicines demand is higher than its supply (producing opportunities). Counteractive marketingis related to irrational (non rational) demand, with harmfulness in terms of health, consumer and society welfare. Market research provisions medicines demand study and projection, price analysis and rivals medicines, market capacity determination and enterprise’s share on it. Such kind of analysis assists to estimate market opportunities and determine attractive marketing activity direction, where enterprise can acquire competitive advantages
10
Gaedeke, Ralph M., Dennis H. Tootelian, and Eric E. Sanders. "Value of Services Provided by Pharmaceutical Companies." Health Marketing Quarterly 17, no. 1 (September 1999): 23–31. http://dx.doi.org/10.1300/j026v17n01_03.
Full textDissertations / Theses on the topic "Pharmaceutical Marketing Services Inc"
1
Müller, Sabine, Veronika Safarova, and Michelle Villavicencio. "Analysing the Communication Gap in a Business-to-Business Setting : A Qualitative Study of Alpha Inc. Sweden and its After Sales Service." Thesis, Mälardalens högskola, Akademin för ekonomi, samhälle och teknik, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:mdh:diva-25335.
Full text
2
Πλακούτση, Αγγελική. "Η εικόνα των καταναλωτών για το ελληνικό φαρμακείο και ο βάθμος ικανοποίησης τους από τις παρεχόμενες φαρμακευτικές υπηρεσίες." Thesis, 2011. http://nemertes.lis.upatras.gr/jspui/handle/10889/4494.
Full textAbstract:
Η παρούσα εργασία εκπονήθηκε στο πλαίσιο του Μεταπτυχιακού Προγράμματος Σπουδών, στην κατεύθυνση “Φαρμακευτικό Μάρκετινγκ”, του τμήματος Φαρμακευτικής του Πανεπιστημίου Πατρών.
Σκοπός της εργασίας ήταν να ερευνηθούν τα κριτήρια με βάση τα οποία οι καταναλωτές επιλέγουν το φαρμακείο που θα κάνουν τις αγορές τους, την εικόνα που έχουν για το ελληνικό φαρμακείο και κυρίως για το φαρμακοποιό, και το βαθμό ικανοποίησής τους από τη στάση του φαρμακοποιού και γενικά από τις υπηρεσίες που παρέχονται στο φαρμακείο.
Παράλληλα, επιδίωξη της εργασίας ήταν να μελετήσει τις σχέσεις που μπορεί να υπάρχουν:
• μεταξύ των διαφόρων χαρακτηριστικών του φαρμακείου, ως προς τη σημαντικότητά τους, για τους καταναλωτές κατά την επιλογή του φαρμακείου που θα πραγματοποιήσουν τις αγορές τους,
• μεταξύ των χαρακτηριστικών-κριτηρίων αυτών και δημογραφικών χαρακτηριστικών,
• μεταξύ της εικόνας των καταναλωτών για το φαρμακοποιό ως επιστημονικό σύμβουλο και δημογραφικών χαρακτηριστικών,
• μεταξύ του βαθμού ικανοποίησης από τις παρεχόμενες φαρμακευτικές υπηρεσίες και δημογραφικών χαρακτηριστικών.
Ειδικότερα στοχεύουμε στη συσχέτιση των δημογραφικών χαρακτηριστικών με: (α) το κριτήριο της τοποθεσίας του φαρμακείου, (β) το κριτήριο της εξυπηρετικότητας στο φαρμακείο, (γ) το κριτήριο του διαθέσιμου χώρου πάρκινγκ του φαρμακείου, (δ) το κριτήριο της ωραίας διακόσμησης του φαρμακείου, (ε) το κριτήριο της παρουσίας εξειδικευμένου επιστήμονα (π.χ. αισθητικός, διαιτολόγος) στο φαρμακείο, (στ) την εικόνα του φαρμακοποιού ως επιστημονικού συμβούλου, (ζ) το βαθμό ικανοποίησης των καταναλωτών από τις παρεχόμενες φαρμακευτικές υπηρεσίες.
Για το σκοπό αυτό χρησιμοποιήθηκε πρωτότυπο ερωτηματολόγιο με ερωτήσεις κλειστού τύπου. Το σχήμα που εφαρμόστηκε για την επιλογή του δείγματος είναι η “στρωματοποιημένη τυχαία δειγματοληψία.” Ερωτήθηκαν 200 άτομα σε δείγμα δύο επαρχιακών πόλεων, οι οποίες επιλέχθηκαν σύμφωνα με τη “βολική δειγματοληψία.” Η συλλογή των στοιχείων έγινε τον Ιούλιο του 2008. Από την ανάλυση των δεδομένων βρέθηκε ότι η σειρά μειούμενης σημαντικότητας των κριτηρίων, που επηρεάζουν τους καταναλωτές στην επιλογή του φαρμακείου που θα κάνουν τις αγορές τους, είναι η εξής: η βολική τοποθεσία, οι χαμηλές τιμές, το επίπεδο εξυπηρέτησης, ο ευγενικός φαρμακοποιός, η μεγάλη ποικιλία των προϊόντων, η καλή φήμη του φαρμακείου, η παρουσία εξειδικευμένου επιστήμονα στο φαρμακείο, η ωραία διακόσμηση του φαρμακείου.
Επίσης, βρέθηκε ότι δεν υπάρχει στατιστικά σημαντική συσχέτιση: (α) μεταξύ του φύλου και του κριτηρίου της εξυπηρετικότητας, (β) μεταξύ του επιπέδου μόρφωσης, της ηλικίας, του εισοδήματος, και του αριθμού των παιδιών των καταναλωτών, με την εικόνα που έχουν για τον φαρμακοποιό ως επιστημονικό σύμβουλο, (γ) μεταξύ του φύλου, της ηλικίας, του επιπέδου μόρφωσης, της οικογενειακής κατάστασης, και της επαγγελματικής κατάστασης των καταναλωτών, με τον βαθμό ικανοποίησης των καταναλωτών από την αξία των υπηρεσιών που παρέχουν τα φαρμακεία σήμερα.
Ακόμη, βρέθηκε ότι οι άνδρες θεωρούν πιο σημαντικό το διαθέσιμο χώρο πάρκινγκ σε ένα φαρμακείο προκειμένου να το επιλέξουν για τις αγορές τους, σε σχέση με τις γυναίκες. Επιπλέον, οι γυναίκες θεωρούν σημαντικότερο κριτήριο την ωραία διακόσμηση στο φαρμακείο από τους άντρες για την επιλογή του φαρμακείου. Σημαντικό εύρημα είναι ότι οι γυναίκες συμφωνούν περισσότερο από τους άντρες στο ότι ο φαρμακοποιός είναι κυρίως επιστημονικός σύμβουλος.This study is a survey of customers shopping in Greek pharmacies and their satisfaction from purchases, pharmaceutical services and store atmosphere. Concretely, the objective is to study the following: i) the factors that affect patients to choose a pharmacy for their shopping (aesthetical, designing, personnel), ii) patients’ view for the role of pharmacists (consulters, businessman, doctor’s assistant), iii) patients’ satisfaction from pharmaceutical services. The data collected from a sample of 200 patients-customers, in two small Greek cities. The sampling method was convenient sampling and the sampling plan was stratified random sampling. Age was used as layer sampling. SPSS (statistical package for the social sciences) statistical program was used for the inductive data analysis. From the statistical analysis, we found the importance of some factors that affect patients in choosing pharmacy for their shopping. When choosing a pharmacy, its location was considered the most important factor. Less important factors were prices, service, personnel’s attitude, wide choice, specialized scientist in pharmacy (dietician) and pharmacy decoration. It was also found that for men is very important the available parking in order to choose pharmacy. Women consider more important beautiful pharmacy decoration in order to choose it. Relation was not found between sex and pharmacy personnel service, and, location and age. The role of the pharmacy personnel was viewed in three different ways, as: counselor, doctor’s assistant and businessman. It was also believed that sometimes the pharmacy personnel might play a double role-both as doctor and pharmacist. Women, married, separated thought that pharmacist is basically counselor. It is very important that women think of pharmacist as mainly scientific advisor, more than men. It is important that patients believe that pharmacists need more scientific education. Relation was not found between education, age, income, number of children and pharmacy’s view as scientific advisor. Customers were satisfied from their pharmacist’s: behavior-kindness, secrecy, help choosing the right medicine, professional consultation. A percentage of 37% of patients are very satisfied from their pharmacist’s advice. 50% of patients are very satisfied from the existing schedule of pharmacies. Important relation was found between patients’ income, children number and satisfaction. Patients having income above 3000 were more satisfied from pharmaceutical services, than customers with lower income, maybe because they do not experience health system with the same way. Customers with one or two kids feel more satisfaction from pharmaceutical services, maybe because they are new parents and this feeling is unknown. Relation was not found between sex, age, education, professional situation and satisfaction from pharmaceutical services. Customers are more satisfied: i) when their pharmacist helps them to select the correct medicine, despite when their pharmacist provides them some advice with regard to their medication treatment, ii) when their pharmacist is secretive concerning their health problems despite when their pharmacist has polite behavior. The results of research can be the reason for same or similar researches in the future in Greece, as health products are a very important part of economy.
Books on the topic "Pharmaceutical Marketing Services Inc"
1
Commission, Monopolies and Mergers. IMS Health Inc and Pharmaceutical Marketing Services Inc: A report on the merger situation. London: Stationery Office, 1999.
Find full text
2
Wellcome Institute for the History of Medicine. Pills and profits: The selling of medicines since 1870 : an exhibition at the Wellcome Institute for the History of Medicine, 29 April to 19 August 1994. [London]: Wellcome Trust, 1994.
Find full text
4
Clark, Malcolm, ed. Herman Miller, Inc., buildings and beliefs. Washington, D.C: American Institute of Architects Press, 1994.
Find full text
5
Medis Health and Pharmaceutical Services Inc., ed. Medis: The story of Canada's leading drug wholesaler. Kirkland, Quebec: Medis Health and Pharmaceutical Services, 1994.
Find full text
6
Office, General Accounting. Medicaid: Methods for setting nursing home rates should be improved : report to the Secretary of Health and Human Services. Washington, D.C: GAO, 1986.
Find full text
7
Lawless, Linda L. Therapy, Inc.: A hands-on guide to developing, positioning, and marketing your mental health practice in the 1990's. New York: Wiley, 1997.
Find full text
8
United States. Congress. Senate. A bill to amend title XVIII of the Social Security Act to provide for standardized marketing requirements under the Medicare Advantage program and the Medicare prescription drug program and to provide for State certification prior to waiver of licensure requirements under the Medicare prescription drug program, and for other purposes. Washington, D.C: U.S. G.P.O., 2007.
Find full text
9
Design like Apple: Seven principles for creating insanely great products, services, and experiences. Hoboken, N.J: Wiley, 2012.
Find full text
10
Horgan, Constance M. Study to evaluate the use of mail service pharmacies. Waltham, MA: Bigel Institute for Health Policy, Brandeis University, 1990.
Find full textBook chapters on the topic "Pharmaceutical Marketing Services Inc"
1
Orti, Jose Enrique De la rubia, Eva Maria Giner Larza, Lynn Summerfield, and Daniel de la Rubia Orti. "Product Placement in the Pharmaceutical Industry." In Advances in Marketing, Customer Relationship Management, and E-Services, 170–88. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-8342-6.ch009.
Full textAbstract:
While physician-oriented marketing remains the largest factor in drug advertising and direct-to-consumer advertising has increased its budget during the last few years (IMS Health, 2001), pharmaceutical brands are exploring new ways to target consumers in a softer way. Product placement in entertainment media allows the promotion of brand drugs in a natural and entertaining context. Using a case study methodology, this chapter analyses the use of product placement of a brand drug (Sinemet) in the television series ER (NBC). To do so, first of all product placement definition and main marketing goals are provided. Then the authors address the legal framework of product placement for brand drugs in television series. Using parasocial attachment theory (Russell & Stern, 2006) and meaning transfer theory (McCracken, 1986) the relationship between actors, brand drugs, and spectators is analyzed. The type of placement and expected outcomes of brand drugs product placement are also analyzed.
2
Samanta, Irene. "The Effect of the Marketing Strategy in Performance of the Pharmaceutical Sector." In Advances in Marketing, Customer Relationship Management, and E-Services, 278–89. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-2139-6.ch013.
Full textAbstract:
The aim of this research is to examine the impact of Marketing Strategy possesses in pharmaceutical sector in Greece and define the competitive and organizational benefits accumulate from the procedure. A quantitative survey was conducted with a sample of pharmaceutical firms. The method used is Factor analysis and a Multivariable Regression Model in order to forecast the total performance of the organization. The importance of the Marketing Strategy in the current economic conditions provides a practical indication of marketing decision making and if managed carefully and closely monitored it can offer a number of direct competitive benefits to the industries.
3
Kalia, Shalini, Neha Mittal, and Rohit Arora. "Maximizing Employee On-Boarding." In Advances in Marketing, Customer Relationship Management, and E-Services, 288–316. IGI Global, 2014. http://dx.doi.org/10.4018/978-1-4666-4357-4.ch023.
Full textAbstract:
A pharmaceutical company faced with the challenge of high attrition of new hires, took the initiative of revamping its employee on-boarding program. The gaps in the existing processes were identified by the HR team and customized solutions were implemented ranging from operational to strategic solutions.
4
Bansal, Divya, Srilakshmi Rao, and Karpagam T. "An Empirical Study on Pharmaceutical and Personal Care Stocks Using Sharpe's Single-Index Model." In Advances in Marketing, Customer Relationship Management, and E-Services, 139–49. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-7231-3.ch010.
Full textAbstract:
As the various avenues for better returns in India are slowly dwindling due to various global scenarios as well as due to domestic government policies, more and more people are turning towards stock market for better returns. This poses a challenge to the fund managers when they have to construct a portfolio, which maximizes return and minimizes risk. This has become more and more challenging in the recent years as the investors are also becoming more knowledgeable. Timely and correct investment decision on the part of the investor requires an in-depth knowledge of the stock that he intends to procure and the theories behind portfolio management. This chapter mainly focuses on construction of an optimal portfolio comprising of top pharmaceutical companies and FMCG companies in India. Sharpe ratio return analysis is the tool that is used to construct the optimal portfolio. Monthly returns data of last 10 years of the said companies are regressed against monthly return data of Nifty for better comparison.
5
Camillo, Angelo A., Svetlana Holt, Joan Marques, and Jianli Hu. "Creating Global Competitiveness through Culture and Religion." In Handbook of Research on Effective Marketing in Contemporary Globalism, 335–47. IGI Global, 2014. http://dx.doi.org/10.4018/978-1-4666-6220-9.ch019.
Full textAbstract:
The Halal food industry is of fundamental significance to Muslims around the world as it assures safety and security in their dietary requirements and consumption, which must be Syariah compliant. In Muslim countries especially, the Halal industry is a vital contributor to societal development and national economic growth. Additionally, over the last decade marketers around the globe, too, have been strategically promoting and strengthening the Halal food industry by targeting primarily critical geographic clusters with large Muslim populations. Although the production, certification, and global coordination effort appears to be made largely by Malaysian and Indonesian authorities, the industry is still very fragmented, and scholars attempting to obtain reliable and valid data face serious challenges. Nevertheless, data gathered from non-academic sources indicate that the global Halal market (food and non-food) is estimated to be in excess of US $2.3 trillion, and the volume of the global Halal food sector alone is reaching US $700 billion annually. The portion of the non-food sector is estimated to be even greater, with chemical, healthcare, cosmetics, and pharmaceutical industries to name just a few. Furthermore, the Syariah compliant services, which include finance and banking, logistic, warehousing, and distribution, are rapidly gaining acceptance in the global Halal market. The Halal industry within the global context is an under researched field of study in scientific literature, in business, and in social science. This chapter investigates the strategies used by marketers to globalize the Halal food industry with the aim to gain and sustain international competitive advantage.
6
Barat, Somjit. "The Impact of Indian Movie Industry on Marketization of India, Inc." In Advances in Marketing, Customer Relationship Management, and E-Services, 208–26. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-3150-0.ch012.
Full textAbstract:
This chapter focuses on how the Indian film industry has helped market “India Inc.” to the outside world since the Government of India accorded ‘industry' status to the business of film-making in 1998. Specifically, this article focuses on how the biggest film industry in the world went through decades of chaotic and unprofessional managerial regimes to acquire the status of one of the most sought-after marketing platforms by different entities—both Indian and international. The chapter also discusses how the ‘marriage of convenience' between Indian film world and the game of cricket added fuel to the marketization of the Indian film industry. Overall, this chapter leaves the reader with several interesting and groundbreaking ideas for future research.
7
Schuster, Camille P. "Preparing Students to Use Marketing Technology for Decision-Making." In Advances in Marketing, Customer Relationship Management, and E-Services, 162–73. IGI Global, 2016. http://dx.doi.org/10.4018/978-1-4666-9784-3.ch011.
Full textAbstract:
Organizations have increased expectations for expertise in data analytics by marketing students. The chapter describes the change taking place in business in general and in marketing specifically and the disconnect between demand and supply. While tools have been available to teach marketing research using survey, experimental, and qualitative methodologies. However, a lack of materials and a huge learning curve are major reasons for methodologies for analyzing digital data, big data, or social media data not being used. Teradata, Inc., worked with Marketing Information Systems academics to create TeradataUniversityNetwork.com (TUN) as a place for sharing tools, software, articles, and data so analytics can be taught in the classroom. As of August 2014, (TUN) is a resource for sharing tools, software, articles, and videos that focus on marketing analytics. This chapter describes the range of materials available and how they can be used in the classroom.
8
Medhekar, Anita, and Farooq Haq. "Halal Branding for Medical Tourism." In Emerging Research on Islamic Marketing and Tourism in the Global Economy, 160–89. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-6272-8.ch008.
Full textAbstract:
This chapter explores the emergence and development of Halal branded hospitals and medical facilities as a product of Medical Tourism for Muslim patients around the world and in India. Halal tourism is a sub-category of spiritual tourism, where one has to abide by the Sharia law to satisfy Muslim customers. The main objective of the chapter is to focus on a niche category of halal medical tourism, where Sharia rules are followed to attract the medical tourist mainly from Islamic countries. This chapter also proposes a typology of Muslim medical tourist's cultural sensitivities and recommends branding and certifying Halal Medical Tourism hospitals, healthcare facilities, pharmaceuticals, products, and services to attract Muslim patients, and provides challenges and opportunities with future research directions. The case studied in this chapter is of the Global Health City, the first Halal Certified Medical Hospital facility in Chennai, India. It presents a model for halal branding of Indian Medical Tourism based on the halal decision-making paradigm for Muslim customers designed by Wilson and Liu (2010). The model presented here indicates attitudes of being rational or emotional and elements reflecting affective and cognitive feelings for Muslim patients seeking halal treatment in halal hospitals.
9
Ingsriswang, Supawadee, and Guisseppi Forgionne. "Stickiness." In Intelligent Support Systems, 153–63. IGI Global, 2002. http://dx.doi.org/10.4018/978-1-931777-00-1.ch012.
Full textAbstract:
The past few years have borne witness to a revolution in business with acceleration in the use of the World Wide Web to support or, in many cases, supplant traditional modes of marketing and selling products and services. The Internet consumer base is continually growing. According to a report conducted by Computer Industry Almanac, Inc. (www.c-i-a.com, 1999), 490 million people around the world will have online access by the year 2002. With the rapid increase in the number of online consumers, the managers and marketers are moving to exploit this opportunity to reach millions of customers worldwide. Between 1997-1999, Internet hosts grew from 16 million to over 72 million worldwide (www.isc.org, 2000). The explosive growth of websites raises the question to the Web designer and marketer about how to attract consumer attention to their sites and how to differentiate their sites from other sites.
10
Tansey, Michael. "What about the Customer? The Patient’s Dilemma." In Intelligent Drug Development. Oxford University Press, 2014. http://dx.doi.org/10.1093/oso/9780199974580.003.0016.
Full textAbstract:
Apparently no one was listening to Sir William. In a study carried out 80 years after Osler’s exhortation, physicians interrupted patients, on average, after 18 seconds (H. Beckman and R. Frankel, 1984). It is common to take for granted the very people who are essential for our continued paid employment and the success of our endeavors, namely our customers. For example, some airline staff refer to passengers as “self-loading freight” or SLF (www. pprune.org), which, though mildly amusing and certainly accurate, is hardly indicative of a warm and friendly service-focused attitude. Attitudes in the pharmaceutical business are no different. Throughout the development and marketing cycles, the emphasis is primarily on satisfying intermediaries such as regulators, opinion leaders, prescribers, and insurers. Important though these intermediaries may be, they are not the customers. Patients are the sole customers. Only patients pay for their drugs (whether directly or through insurance or taxation) and only patients consume pharmaceutical products and experience the benefits and adverse effects. Only patients decide whether or not to continue taking a drug. Put simply, if there were no patients, there would be no pharmaceutical industry. Sir William Osler was talking in the context of clinical history taking and examination, but his comment applies more broadly. Over the past 10 to 15 years, there has been slowly increasing recognition that there are virtually no aspects of development, registration, and commercialization of a drug in which listening to the patient does not improve the outcome. Guidance issued by the FDA (Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, U.S. Department of Health and Human Services, Food and Drug Administration, December 2009) has gone a long way in helping to redirect and focus the industry. The implications are broad and go beyond the traditional areas of patient input such as quality of life measures and can significantly influence trial design, approval, labeling, and reimbursement.
Conference papers on the topic "Pharmaceutical Marketing Services Inc"
1
Trucco, M. Y., and S. Amirkhanova. "Transforming Pharmaceutical Marketing Through e-detailing: Case Studies and Recommendations." In The 8th IEEE International Conference on E-Commerce Technology and The 3rd IEEE International Conference on Enterprise Computing, E-Commerce, and E-Services (CEC/EEE'06). IEEE, 2006. http://dx.doi.org/10.1109/cec-eee.2006.92.
Full text
2
Brickner, Robert H. "Behind the Scenes: Historic Agreement to Develop U.S. Virgin Islands’ First Alternative Energy Facilities." In 18th Annual North American Waste-to-Energy Conference. ASMEDC, 2010. http://dx.doi.org/10.1115/nawtec18-3516.
Full textAbstract:
In the summer of 2009, Governor John P. DeJongh, Jr. announced that the Virgin Islands Water and Power Authority (WAPA) had just signed two 20-year Power Purchase Agreements, and the Virgin Islands Waste Management Authority (VIWMA) had signed two 20-year Solid Waste Management Services Agreements with affiliates of Denver-based Alpine Energy Group, LLC (AEG) to build, own, and operate two alternative energy facilities that will serve the residents of St. Croix, St. John, and St. Thomas. The alternative energy facilities, to be built on St. Croix and St. Thomas, have a projected cost of $440 million and will convert an estimated 146,000 tons per year of municipal solid waste into refuse-derived fuel (RDF) using WastAway Services® technology, which will be combined with petroleum coke as fuel in fluidized bed combustion facilities to generate steam and electric power. These sustainable projects will provide 33 MW of electric power to St. Thomas and St. John and 16 MW of electric power to St. Croix, and will help to provide long-term cost stability for electric power and solid waste management in the Territory. Construction is expected to start in spring 2010 with an anticipated completion date during the fourth quarter of 2012. This procurement is a significant achievement for the U.S. Virgin Islands. When the projects are fully implemented, they will allow the Territory to reduce its dependence on oil, recover the energy value and certain recyclable materials from its municipal solid waste, and divert this waste from landfill. Since VIWMA has the responsibility to collect and/or dispose of solid waste year-round, having a system incorporating multiple solid waste processing lines and an adequate supply of spare parts on hand at all times is crucial to meeting the daily demands of waste receiving and processing, and RDF production. Also, with the location of the US Virgin Islands in a hurricane zone, and with only one or two combustion units available in each Project, the ability to both stockpile waste pre-RDF processing and store the produced RDF is very important. Gershman, Brickner & Bratton, Inc. (GBB)’s work has included a due diligence review of the Projects and providing professional support in VIWMA’s negotiations with AEG. GBB’s initial primary assignment centered on reviewing the design and operations of the RDF processing systems that will be built and operated under the respective Service Contracts. VIWMA needed to undertake a detailed technical review of the proposed RDF processing system, since this was the integration point of the waste collection system and waste processing/disposal services. GBB, in association with Maguire, was requested to provide this review and present the findings and opinions to VIWMA. In the completion of this effort, which included both a technical review and participation in negotiations to advance the Service Contracts for the Projects, GBB made direct contact with the key equipment suppliers for the Projects proposed by AEG. This included Bouldin Corporation, the primary RDF processing system supplier, with its patented WastAway technology, and Energy Products of Idaho, the main thermal processing equipment supplier, with its fluidized bed combustion technology and air pollution control equipment. Additionally, since the combustion systems for both Projects will generate an ash product that will require marketing for use and/or disposal over the term of the Service Contracts, GBB made contact with LA Ash, one of the potential subcontractors identified by AEG for these ash management services. Due to the nature of the contract guarantees of VIWMA to provide 73,000 tons per year of Acceptable Waste to each Project for processing, VIWMA authorized GBB to perform a current waste stream characterization study. Part of this effort included waste sorts for one week each in February 2009 on St. Croix and March 2009 on St. Thomas, with the results shared with VIWMA and AEG, as compiled. The 2009 GBB waste stream characterization study incorporated historical monthly waste weigh data from both the Bovoni and Anguilla Landfills that were received from VIWMA staff. The study has formed a basis for continuing to augment the waste quantity information from the two landfills with the additional current monthly results compiled by VIWMA staff going forward following the waste sorts. The final GBB report was published in December 2009 and includes actual USVI landfill receipt data through August 31, 2009. The information contained in this document provides the underpinnings to allow for better tracking and analysis of daily, weekly and monthly waste quantities received for recycling, processing and disposal, which are important to the overall waste processing system operations, guarantees and cost projections. GBB’s annual projections are that the total waste on St. Croix is currently over 104,000 tons per year and over 76,000 tons per year on St. Thomas. The thermal processing technology selected for both Projects is a fluidized bed process, employing a heated bed of sand material “fluidized” in a column of air to burn the fuel — RDF and/or Pet Coke. As such, the solid waste to be used in these combustion units must be size-reduced from the myriad of sizes of waste set out at the curb or discharged into the large roll-off boxes or bins at the many drop-off sites in the US Virgin Islands. While traditional RDF would typically have several days of storage life, the characteristics of the pelletized RDF should allow several weeks of storage. This will be important to having a sound and realistic operating plan, given the unique circumstances associated with the climate, waste moisture content, island location, lack of back-up disposal options and downtime associated with the Power Generation Facility. During the negotiations between AEG and VIWMA, in which GBB staff participated, in addition to RDF and pelletized RDF as the waste fuel sources, other potential fuels have been discussed for use in the Projects and are included as “Opportunity Fuels” in the Service Contracts. These Opportunity Fuels include ground woody waste, dried sludges, and shredded tires, for example. Therefore, the flexibility of the EPI fluidized bed combustion boilers to handle multi-fuels is viewed as an asset over the long term, especially for an island location where disposal options are limited and shipping materials onto and off of each island is expensive. This presentation will provide a unique behind-the-scenes review of the process that led to this historic agreement, from the due diligence of the proposed technologies, to implementation planning, to the negotiations with the contractor. Also discussed will be the waste characterization and quantity analysis performed in 2009 and the fast-track procurement planning and procurement of construction and operating services for a new transfer station to be sited on St. Croix.